We are live on ! Find out more
RAIN

Rain Oncology Inc. Common Stock
RAIN

Delisted

RAIN was delisted on the 25th of January, 2024.

Back to rankings

38 hedge funds and large institutions have $73.9M invested in Rain Oncology Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less capital invested

Capital invested by funds: $77.7M → $73.9M (-$3.81M)

5% less funds holding

Funds holding: 40 → 38 (-2)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

Holders
38
Holders Change
-2
Holders Change %
-5%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
11
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$5.56M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.13M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$765K
4
Citadel Advisors
Citadel Advisors
Florida
+$357K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$142K

Top Sellers

Rank Fund Capital Flow
1
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$158K
2
Bank of America
Bank of America
North Carolina
-$128K
3
Millennium Management
Millennium Management
New York
-$65.7K
4
First Trust Advisors
First Trust Advisors
Illinois
-$62K
5
Goldman Sachs
Goldman Sachs
New York
-$56K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$17.2M – – –
PA
2
Perceptive Advisors
New York
$12.1M – – –
CAM
3
Cormorant Asset Management
Massachusetts
$11.4M – – –
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$7.79M +$5.56M +885,553 +121%
SB
5
Samsara BioCapital
California
$7.62M – – –
BC
6
Boxer Capital
California
$5.73M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.14M – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$1.84M +$765K +121,808 +48%
UOC
9
UBS O'Connor
Illinois
$1.59M -$42.7K -6,800 -2%
LCM
10
Laurion Capital Management
New York
$1.53M – – –
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$1.21M +$1.13M +180,000 +264%
BlackRock
12
BlackRock
New York
$673K -$25.4K -4,052 -3%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$610K – – –
WP
14
Woodline Partners
California
$584K – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$363K +$8.21K +1,307 +2%
Citadel Advisors
16
Citadel Advisors
Florida
$328K +$357K +56,888 +549%
E
17
Ergoteles
New York
$318K -$35.2K -5,604 -8%
State Street
18
State Street
Massachusetts
$114K – – –
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$110K +$142K +22,635 New
Renaissance Technologies
20
Renaissance Technologies
New York
$107K +$43.9K +7,000 +47%
Bank of America
21
Bank of America
North Carolina
$96K -$128K -20,468 -51%
Millennium Management
22
Millennium Management
New York
$92K -$65.7K -10,465 -36%
CS
23
Credit Suisse
Switzerland
$88K +$113K +17,992 +224,900%
Northern Trust
24
Northern Trust
Illinois
$65K -$7.63K -1,215 -8%
PA
25
Parallel Advisors
California
$61K – – –
1
2

RAIN Hedge Fund Activity: Q3 2022 in Review

38 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q3 2022, worth a combined $73.9M — down 4.9% from $77.7M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of RAIN and 5 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 8 added.

The largest buyer was Janus Henderson Group, adding an estimated $5.56M. The largest seller was Thrivent Financial for Lutherans, exiting entirely with an estimated $158K sold.

  • 38 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q3 2022, down from 40 in Q2 2022.
  • Funds reported $73.9M of Rain Oncology Inc. Common Stock stock for Q3 2022, down 4.9% quarter-over-quarter.
  • 5 funds opened new Rain Oncology Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of -1 holder.
  • The largest Rain Oncology Inc. Common Stock buyer in Q3 2022 was Janus Henderson Group, an estimated $5.56M added.
  • The largest Rain Oncology Inc. Common Stock seller in Q3 2022 was Thrivent Financial for Lutherans, an estimated $158K sold.

Based on aggregated 13F filings for Q3 2022.